Discrepancies between the material output of cell culture and fermentation and the capacity of downstream purification has long been a point of debate in biotechnology. The bad news, if one can call ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...